Objectives: Hydroxyethyl starch 200 is associated with renal impairment in sepsis, but hydroxyethyl starch 130/0.4 and gelatin are considered to be less harmful. We hypothesized that fluid therapy with only crystalloids would decrease the incidence of acute kidney injury.
I n recent years, meta-analyses and clinical trials have found that colloid or crystalloid resuscitation lead to similar survival (1, 2) . Fluid choice therefore is deemed to be of secondary importance and sepsis management guidelines leave the choice of fluid to the user (3) . Hydroxyethyl starch (HES) is now the most commonly used colloid, followed by gelatins, human albumin, and dextrans (4 -6) .
Although there is growing evidence that the use of some starch solutions may increase renal failure and mortality (7) (8) (9) (10) , "modern third-generation" starches with low molecular weight (HES 130/0.4) are claimed to be safe for use in the intensive care unit (ICU) (11, 12) . In 2007, the Food and Drug Administration approved use of 6% HES 130/ 0.4 for the treatment and prophylaxis of hypovolemia.
Recent systematic reviews, however, found that published evidence was insufficient to uphold the claim that lowmolecular-weight starches have fewer side effects than older starches (9) and identified only one exploratory trial with HES 130/0.4 in the setting of ICU or sepsis patients (10) .
We therefore replaced 6% HES 130/ 0.4 with 4% gelatin in the ICU, as well as in the emergency department and in the operating rooms. To our surprise, the need for renal replacement therapy (RRT) remained unchanged at 36%. Furthermore, both synthetic colloids were associated with a dose-related increase of renal failure (13) .
Gelatins are thought to be less nephrotoxic, but this notion is derived from trials in severe sepsis and kidney transplantation patients in whom gelatins served as control to older HES solutions (8, 14) . Randomized controlled trials that address gelatin efficacy and safety are scarce.
Here, we report on the clinical outcomes of severe sepsis patients from three sequential treatment periods. During the first two periods, patients were sequentially treated with the synthetic colloids HES and gelatin and additional crystalloids. In the third period, patients received only crystalloids. Apart from that, treatment protocols for severe sepsis patients remained unchanged throughout.
MATERIALS AND METHODS

Patients
The study population consisted of all patients with severe sepsis or septic shock treated in a 50-bed interdisciplinary surgical ICU of a university hospital. Patients were excluded from analysis if they had chronic renal failure requiring hemodialysis before ICU admission or had been enrolled in a randomized HES trial (7) . The local ethics board waived the need for informed consent because of the observational nature of the study.
Procedures
Before July 2006, standard fluid treatment of hypovolemia in our ICU, emergency department, and the operating room consisted of a combination of crystalloids and synthetic colloids. In the first study phase from January 1, 2005 until June 30, 2005, patients were treated with predominantly 6% HES (6% HES 130/0.4%; Voluven; Fresenius-Kabi Bad Homburg) and crystalloids (HES group). Because of concerns about HES-related nephrotoxicity, HES solutions were replaced by 4% gelatin. From January 1, 2006 to June 30, 2006, all patients with severe sepsis or septic shock were treated with 4% modified gelatin (Gelafusal; Serumwerk Bernburg AG, Bernburg, Germany) and crystalloids (gelatin group). We prospectively planned to compare the effects of the different fluid regimens in a before-andafter study with sequential treatment periods of 6 months that were separated by a washout period of 6 months to allow for a complete implementation of the new standard fluid. The analysis of the first two treatment periods was published previously (13) and revealed that the need for RRT was not different between the two cohorts of ICU patients receiving HES or gelatin. We therefore extended our study. Gelatin was abolished and replaced by crystalloids starting in July 2006. Until now, only balanced crystalloid solution (Jonosteril; Fresenius Kabi, Bad Homburg, Germany) has been used in the ICU, emergency department, and operating room, except in patients with hyperkalemia who receive normal saline (NaCl 0.9%; Fresenius Kabi, Bad Homburg, Ger-many). Study phase III lasted from September 2008 until June 2009. All patients in phase III were treated only with crystalloids (crystalloid group).
Therapy for sepsis followed institutional standard operating procedures based on the guidelines of the Surviving Sepsis Campaign (3) and the German Sepsis Society (15) . During the HES and gelatin phase, the indication for colloid administration was left to the discretion of the attending critical care physician. Standard hemodynamic management included vasopressors with noradrenaline to maintain a mean arterial pressure Ͼ65 mm Hg, in addition to repeated fluid challenges with crystalloids and synthetic colloids (gelatin or hydroxyethyl starch) to allow the lowest possible dose of vasopressors. If needed, dobutamine (up to a dose of 10 g/kg/min) or epinephrine (up to 0.15 g/kg/min) was added. Extended hemodynamic monitoring with pulmonary artery catheter (Swan-Ganz CCOmbo; Edwards Life Sciences, Unterschleissheim, Germany) or PiCCO (Pulsiocath 5-Fr Thermodilution Catheter; Pulsion Medical Systems Mü nchen, Germany) was considered if the required vasopressor dose increased Ͼ0.4 g/kg/min of noradrenaline. Central venous oxygen saturation was measured at least two times per day from blood samples drawn from the central venous catheter.
Human albumin was not used for volume replacement. Its use was restricted to treatment of severe hypoalbuminemia Ͻ15 mmol/mL by 20% human albumin (Albunorm 20%; Octapharma, Langenfeld, Germany).
Continuous veno-venous hemodialysis was the single modality for RRT in our ICU during all study periods. Indications for RRT in our ICU included diuretic-resistant oliguria (urine output Ͻ0.5 mL/kg body weight) persistent for 6 hrs or anuria persistent for 3 hrs despite adequate volume therapy or associated with volume overload with threatened or established pulmonary edema, the presence of hyperkalemia, or severe metabolic acidosis (pH Ͻ7.1).
Primary and Secondary Outcomes: Definitions and Data Collection Methods
The primary end point for our analysis was the development of acute kidney injury (AKI). New occurrence of RRT was a co-primary end point. We defined AKI according to the standardized and validated RIFLE criteria, including separate criteria for creatinine and urine output, and using the criteria that led to the worst outcome. Urine output was measured over 24 hrs and calculated back to 6-or 12hourly values (16) . Accordingly, RIFLE "risk" was fulfilled by a 1.5-fold increase in serum creatinine levels or urine output Ͻ0.5 mL/ kg/hr (or both) for Ն24 hrs, RIFLE "injury" by a two-fold increase in serum creatinine levels or urine output Ͻ0.3 mL/kg/hr (or both) for Ն24 hrs, and RIFLE "failure" was defined by a three-fold increase in serum creatinine levels and new RRT or serum creatinine Ն354 mol/L with an acute rise of at least 44 mol/L or urine output Ͻ0.3 mL/kg/hr Ն24 hrs (or both) or anuria Ն12 hrs for Ն24 hrs. AKI was defined by one or more RIFLE criteria or new occurrence of RRT. Groups included only patients for whom the entry criterion was the most severe classification, i.e., patients in the RIFLE risk group had no more severe injury than that defined by RIFLE risk.
Secondary end points were cumulative fluid doses, total fluid balance, need for mechanical ventilation, maximum degree of organ failure as assessed by Sequential Organ Failure Assessment (SOFA) score, vasopressor use, need for blood products, ICU length of stay, and ICU and hospital mortality. Total fluids were defined as all intravenous fluids administered as maintenance or bolus fluids or for intravenous drug administrations, including blood products and human albumin, parenteral and enteral feeding solutions, and any oral intake. Creatinine clearance was determined from serum creatinine using the Cockcroft-Gault formula (17) . Study period was length of stay in the ICU.
Data recorded on admission included age, gender, body weight, referring facility, and surgical procedures preceding admission. Screening for the presence of severe sepsis was performed routinely by the senior physicians in our ICU and documented by trained research nurses. The main source of sepsis was also documented. The Simplified Acute Physiology Score II and SOFA scores were calculated within 24 hrs of admission by the attending physician who was in charge of the patient.
Data were collected prospectively from vital sign monitors, ventilators, and infusion pumps and automatically recorded by a clinical information system. The clinical information system (Copra System GmbH, Sasbachwalden, Germany) provided staff with complete electronic documentation, order entry (e.g., medication, fluid dose, and duration), and direct access to laboratory and microbiology results. We recorded the use of nephrotoxic drugs, i.e., nonsteroidal anti-inflammatory drugs, diuretics, angiotensin-converting enzyme inhibitors, antimicrobials and antimycotics, and iodinated contrast media. Data on ICU and hospital length of stay and ICU and hospital mortality were collected for all patients.
Severe sepsis was defined as the presence of a defined focus on infection and at least two of the four Systemic Inflammatory Response Syndrome criteria and infection-related organ dysfunction (18) . A defined focus on infection was defined by either an organism cultured from blood or a sterile site or an abscess or volume of infected tissue (e.g., pneumonia, peritonitis, skin or soft tissue infection). Infection-related organ dysfunction was considered to be present if at least one of the following applied: respiratory, hematologic, or hepatic SOFA score Ͼ1 and cardiovascular SOFA score of 1, 3, or 4 or renal SOFA score Ͼ2. Organ dysfunction was defined previously (7) .
Statistical Analysis
All analyses were performed in SPSS version 17.0 and R version 2.11.1 (R Development Core Team 2010; R Foundation for Statistical Computing, Vienna, Austria). All reported p values are two-sided.
For univariate analyses, we applied the t test or the Mann-Whitney test and Fisher exact test for continuous and categorical variables, respectively. In case of primary and secondary outcomes, resulting p values were adjusted by the Bonferroni-Holm method. Otherwise, the unadjusted p values are reported.
In addition, forward and backward stepwise multiple logistic regression analysis based on Akaike information criterion was performed to identify risk factors for AKI and RRT. The resulting model was checked by the Hosmer-Lemeshow goodness-of-fit test as well as the area under the receiver-operating characteristic curve. In a second step, we added period effects of HES and gelatin as categorical variables with crystalloids as reference category. Thereafter, we added variables for the total fluid amount when the three periods were analyzed separately. For the doseresponse relationship between total fluid amount and AKI and RRT, we computed linear and quadratic fits.
RESULTS
Participants
A total number of 400 patients were treated for severe sepsis in our ICU during the three sequential study periods. Fifty-four patients fulfilled exclusion criteria (chronic renal failure requiring hemodialysis before ICU admission, n ϭ 45; participation in a randomized controlled HES trial described previously, n ϭ 9) (7) .
One hundred eighteen patients received HES 6%, 87 received gelatin 4%, and 141 patients received crystalloids. The baseline characteristics of patients were similar except for fewer patients with cancer in the HES group and fewer patients with an abdominal source of sepsis in the HES and gelatin groups, and fewer patients with abdominal surgery and more patients with cardiac/thoracic surgery in the gelatin group. SOFA score was lower in the HES group, but creatinine, creatinine clearance, and Simplified Acute Physiology Score II scores did not differ between groups (Table 1 ).
Hemodynamics and Fluid Balance
Hemodynamics and fluid balances were analyzed during the first 14 days of the treatment period in the ICU. Mean arterial pressures were significantly higher in the HES group after day 2 ( Fig.  1) . Although mean heart rates did not differ, mean values for central venous pressure and central venous oxygen saturation were higher in the crystalloid group on single study days ( Fig. 1 ). Noradrenaline use was similar in the first 3 days and significantly higher in the crystalloid group on days 4 -8 and days 10 and 11 ( Fig. 1 ). Daily fluid intake and mean daily fluid balance were significantly higher in the crystalloid group at baseline (day 0) and on day 1 (Fig. 1 ). Fluid volumes are given in Table 2 . The cumulative fluid volumes administered were significantly higher in both the HES and the gelatin groups than in the crystalloid group on day 0 and 1 (Fig. 1) . The total amount of fluids was significantly high in the HES group ( Table 2 ). The ratios of total fluid amounts were 1.47:1 (crystalloid compared to HES group) and 1.44:1 (crystalloid compared to gelatin group) on days 0 -1 and 1.17:1 and 1.21:1 for the first 4 days, respectively. Sequential Organ Failure Assessment score 9 (7-11) a 9 (7-13) 10 (7-12)
The p values were calculated with the Student's t test or the Mann-Whitney test and Fisher's exact test, as appropriate.
a .01 Ͻ p Ͻ .05; b .001 Ͻ p Ͻ .01; c p Ͻ .001; d includes neurosurgical, metabolic, renal urinary tract, and gynecologic procedures; e includes catheter-related, wound, central nervous system, and bloodstream infections and endocarditis. Hydroxyethyl starch and gelatin groups were compared with the crystalloid group. 
Morbidity and Mortality: AKI and RRT
Patient exposure to a range of nephrotoxic drugs did not differ between groups except for a higher use of antimycotics in the HES group and angiotensin-converting enzyme inhibitors in the gelatin group (Supplementary AKI occurred in 47% of patients in the crystalloid group, in 70% of patients in the HES group (adjusted p ϭ .002), and in 68% of patients in the gelatin group (adjusted p ϭ .025; Table 3 ). Patients were allocated to RIFLE classes according to their highest risk. The RIFLE risk and RIFLE injury classes contained few patients who were evenly distributed. The majority of patients were allocated to the RIFLE failure class, 47% of patients after administration of HES (adjusted p ϭ .002), 40% after gelatin (adjusted p ϭ .162), and 25% of patients after crystalloids. RRT tended to occur more frequently in patients who received HES (34%) compared to crystalloids (20%; adjusted p ϭ .086). In the gelatin group, the differences were only significant before p value adjustment (Table 3) .
Severity scores, ICU and hospital mortality, and ICU length of stay did not differ significantly between groups after adjustment of p values, but there was a trend toward shorter ICU length of stay in the crystalloid group (Table 3) .
Multiple logistic regression analysis with AKI as a dependent binary variable showed that baseline creatinine, cardiothoracic surgery, antimycotics, human albumin 20%, iodinated contrast media, HES 6%, and gelatin 4% were independent risk factors. A dose-dependency of adverse effects (per mL/kg body weight) was only apparent for crystalloids with a linear or maybe even quadratic risk increase (Table 4 ). HES and gelatin were also independent risk factors after multiple logistic regression with RRT as dependent variable without an apparent dose-effect relationship for any colloid or crystalloid ( Supplementary Table III [Supplemental Digital Content 1, http://links.lww.com/CCM/A232]).
DISCUSSION
Principal Findings
In severe sepsis patients, a change of fluid replacement regimen from HES and gelatin to only crystalloids was associated with a significantly lower incidence of AKI and RRT. ICU and hospital mortality were similar between the groups. Interestingly, patients in the crystalloid group received more fluid volume and had a more positive fluid balance only on the first two days of treatment in the ICU. The total amount of fluid administered was significantly higher in the HES than in the crystalloid group during the whole ICU stay.
The sequential study cohorts of severe sepsis patients were similar at baseline regarding age, hemodynamics, and serum creatinine. However, patients receiving synthetic colloids less often had an abdominal source of sepsis.
Colloids were associated with higher mean arterial pressure on most study days, whereas on some days central venous oxygen saturation and central venous pressure were higher in the crystalloid group and mean SOFA scores were lower in the colloid groups.
The use of nephrotoxic drugs was not different between study groups except that patients receiving HES also received more antifungals (amphotericin B and fluconazole) and patients receiving gelatin also received more angiotensinconverting enzyme inhibitors. Multivariate analysis suggests that besides administration of HES and gelatin, antifungal medication as well as 20% human albumin, cardiothoracic surgery, and iodinated contrast media are independent risk factors for AKI.
Meaning of the Study in Relation to Other Studies
Adverse effects of starch solutions on renal outcomes have been demonstrated repeatedly in sepsis and other critically ill patients (7-10, 14, 19, 20) . Our findings do not support the hypothesis that modern third-generation starches are devoid of negative effects on kidney function (11, 12) because 6% HES 130/0.4 comprised Ͼ90% of the starches in this study (13) . Experimental data also suggest that impairment of kidney function after 6% HES 130/0.4 and 10% HES 200/0.5 only differs by degree (21) , and a recent experimental study suggests that both 6% HES 130/0.4 and gelatin may induce significantly more impairment of renal function and damage to kidney morphology than crystalloid (22) .
Other investigators also have found that adverse effects of starches or gelatins were related to the cumulative dose (7, 20, 23, 24) . In retrospective observational studies, HES administration in low cumulative doses in the range of 15-20 mL/ kg, which is less than half of the recommended maximum daily dose, was not associated with an increased incidence of AKI or acute renal failure (6, 25) .
The need of RRT that was observed in our study after synthetic colloids was 34% after both HES and gelatin. This rate is considerably higher than the rates observed elsewhere after the use of crystalloids or albumin. In a recent multicenter trial with 537 severe sepsis patients, need for RRT was 18.6% in the Ringer's lactate group and 31% in the HES group; 28-day mortality rates were 24.1% and 26.7%, respectively (7) . In the severe sepsis subgroup of the SAFE trial (n ϭ 1218), which compared 4% albumin to 0.9% saline, RRT occurred in 18.7% of patients assigned to albumin compared to 18.2% of patients assigned normal saline. The 28-day mortality rates were 30.7% and 35.3%, respectively (26) .
A high need for RRT may coincide with a widespread use of synthetic colloids. Synthetic colloids and especially HES solutions are preferred volume expanders in Germany (4, 27) . A representative survey conducted in German ICUs in 2003-2004 found an incidence of acute renal failure in these patients of 42.4% (28) . The survey also documented that 35.2% of patients with severe sepsis and septic shock received synthetic colloids mostly in form of HES 6%, HES 10%, or gelatin (29) .
An international sepsis register documented an overall need for RRT of 21.3% in Ͼ12,000 patients from eight countries. The only European country was Germany, where HES is widely used. Need for RRT in German patients was 33.4%, whereas the RRT rates in non-European countries ranged between 11.7% and 25.9%. Hospital mortality rates for severe sepsis patients were 43.4% in Germany and 49.6% overall (30) . IQR, interquartile range. a Five-fold increase in serum creatinine levels and/or urine output Ͻ0.5 mL/kg/hr for Ն24 hrs; b two-fold increase in serum creatinine levels and/or urine output Ͻ0.3 mL/kg/hr for Ն24 hrs; c three-fold increase in serum creatinine levels and/or renal replacement therapy, serum creatinine Ն354 mol/L with an acute increase of at least 44 mol/L, and/or urine output Ͻ0.3 mL/kg/hr Ն24 hrs or anuria Ն12 hrs for Ն24 hrs; d defined by any RIFLE category; e within 28 days of admission to the intensive care unit. The p values were calculated with the Mann-Whitney test and Fisher's exact test, as appropriate. For p value adjustment, the Bonferroni-Holm method was used. AKI occurred in 47% of patients in the crystalloid group, and significantly more frequently after gelatin 4% (68%) and HES 6% (70%). The need for RRT was also higher in both the HES and the gelatin groups, but the difference was nonsignificant after adjustment for multiple testing. There may be several reasons for the failure to achieve significance. The Bonferroni-Holm adjustment for multiple testing may have been too conservative or the sample size may have been too small, particularly in the gelatin group. Gelatin has a lower molecular weight (30 kDa) than HES (130 kDa) and was used as 4% solution compared to the 6% HES solution. Little is known about the mechanisms of colloid-associated renal impairment (31) . Previous studies (8, 14) suggest that gelatin may have a lesser effect on renal function compared to HES. The lower incidence of acute renal failure with gelatin compared to HES observed in one randomized controlled trial in severe sepsis patients may relate to the fact that in this trial a 3% gelatin solution was compared with a 6% HES solution (8) .
Gelatin-associated side effects may have escaped notice in trials in which gelatin was used in comparison to HES (8, 14, 32) . However, a first report appeared recently that demonstrated a similar degree of vesicle formation in the proximal tubule in septic rats with an increase in serum creatinine and urea concentrations after administration of 10 mL/kg 4% gelatin and 6% HES 130/0.4 (22) .
Our study adds to the findings from prospective studies of critically ill patients, which have found that crystalloidto-colloid volume ratios of only 2:1 or less (1, 7, (33) (34) (35) are necessary to achieve and maintain similar hemodynamic end points. It seems that over longer periods of time, the extent to which colloids are thought to remain in the vasculature is not so much greater than that of crystalloids. Within the first hours after fluid administration, hematocrit decreased more rapidly in the colloid groups, as was shown by Wills et al (35) in children with Dengue shock (HES 200/0.5 or dextran 70), or in smaller studies on preoperative hemodilution (36) , or in healthy volunteers (37) . However, over the following hours, hematocrit values increased more in the crystalloid than in the colloid groups (35) and were no longer different at 24 hrs (36, 37) .
Limitations of This Study and Future Research
This study has several limitations, namely that it was a single-center unblinded study with small sample sizes in all groups, with changes of fluid regimen with possibly extended inception period, post hoc adjusted analyses, and multivariate modeling. Conclusions therefore should be drawn with circumspection. The lack of baseline differences does not preclude the presence of unidentified group differences because of the nonrandomized nature of the study. It remains unclear whether the observed differences in mean arterial pressures are attributable to different patient management. The crystalloid group included more patients with an abdominal source of sepsis. We do not believe this constitutes a confounder, because the multivariate analysis identified no association between source of sepsis and AKI, and the need for RRT was found to be significantly higher in patients with abdominal than pulmonary sepsis in a large European survey (38) . That crystalloids, but not HES or gelatin, were found to have a significant dose-dependent effect on AKI perhaps may be attributable to the smaller number of observations compared to crystalloids. Furthermore, the dose-effect relationship of HES 6% or gelatin 4% might be more complex than a linear or quadratic relation.
Some observations strengthen our findings. The similarity between disease severity not only at baseline but also during the course of the disease, as well as the lack of differences in ICU and hospital mortality between the synthetic colloid and the crystalloid groups, support the assumption that the most likely cause for the increased incidence of AKI must be attributed to synthetic colloid use. Thus, our study generates the hypothesis that not only 6% HES 130/0.4 but also 4% gelatin may be associated with AKI in patients with severe sepsis. This study provides hypothesis generation and calls for high-quality, randomized, controlled trials to provide evidence on the safety of HES 130/0.4 and gelatin. Fortunately, such trials are now underway for HES 130/0.4, such as the CHEST trial (www.clinicaltrials.gov; NCT00935168) comparing HES to normal saline in planned 7000 ICU patients and the 6S trial (www.clinicaltrials.gov; NCT00962156) comparing HES 130/0.4 to Ringer's acetate in planned 800 ICU patients. Study designs can be found on the respective Web sites.
CONCLUSIONS
The results of this study question the superiority of synthetic colloids over crystalloids with respect to their volumesaving potential in severe sepsis. Synthetic colloid use did not lead to a less positive total fluid balance. This challenges a common rationale for their use in patients with severe sepsis. The results from our study place serious doubt on the assumption that third-generation HES 130/0.4 and low-molecular-weight gelatin are innocuous regarding renal function. To date, there is a lack of evidence from welldesigned studies in intensive care to support the widespread use of synthetic colloids. Fortunately, such trials are now underway for 6% HES 130/0.4.
